1. Home
  2. EYEN vs LGVN Comparison

EYEN vs LGVN Comparison

Compare EYEN & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYEN
  • LGVN
  • Stock Information
  • Founded
  • EYEN 2014
  • LGVN 2014
  • Country
  • EYEN United States
  • LGVN United States
  • Employees
  • EYEN N/A
  • LGVN N/A
  • Industry
  • EYEN Biotechnology: Pharmaceutical Preparations
  • LGVN Medicinal Chemicals and Botanical Products
  • Sector
  • EYEN Health Care
  • LGVN Health Care
  • Exchange
  • EYEN Nasdaq
  • LGVN Nasdaq
  • Market Cap
  • EYEN 38.2M
  • LGVN 31.2M
  • IPO Year
  • EYEN 2018
  • LGVN 2021
  • Fundamental
  • Price
  • EYEN $0.10
  • LGVN $1.98
  • Analyst Decision
  • EYEN Buy
  • LGVN Strong Buy
  • Analyst Count
  • EYEN 3
  • LGVN 2
  • Target Price
  • EYEN $12.00
  • LGVN $8.00
  • AVG Volume (30 Days)
  • EYEN 3.7M
  • LGVN 706.5K
  • Earning Date
  • EYEN 11-12-2024
  • LGVN 11-12-2024
  • Dividend Yield
  • EYEN N/A
  • LGVN N/A
  • EPS Growth
  • EYEN N/A
  • LGVN N/A
  • EPS
  • EYEN N/A
  • LGVN N/A
  • Revenue
  • EYEN $31,832.00
  • LGVN $1,852,000.00
  • Revenue This Year
  • EYEN $50,943.04
  • LGVN $161.78
  • Revenue Next Year
  • EYEN $397.57
  • LGVN $8.73
  • P/E Ratio
  • EYEN N/A
  • LGVN N/A
  • Revenue Growth
  • EYEN 2557.10
  • LGVN 141.46
  • 52 Week Low
  • EYEN $0.09
  • LGVN $0.77
  • 52 Week High
  • EYEN $2.57
  • LGVN $23.90
  • Technical
  • Relative Strength Index (RSI)
  • EYEN 18.14
  • LGVN 43.46
  • Support Level
  • EYEN $0.46
  • LGVN $1.93
  • Resistance Level
  • EYEN $0.51
  • LGVN $2.31
  • Average True Range (ATR)
  • EYEN 0.05
  • LGVN 0.16
  • MACD
  • EYEN -0.03
  • LGVN -0.02
  • Stochastic Oscillator
  • EYEN 3.11
  • LGVN 25.09

About EYEN Eyenovia Inc.

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Share on Social Networks: